227 results about "Gout" patented technology

The invention provides a probiotics plant solid beverage for treating hyperuricemia and gout. The solid beverage is prepared by mixing freeze-dried probiotics powder and plant extract with the addition of proper auxiliary materials. The solid beverage comprises the following components: the plant extract, the auxiliary materials and the probiotics, with the sum of the mass percentage of each component being 100%. The plant extract comprises celery seed powder, sophora flower bud powder and platycodon root powder. The invention has an obvious effect on lowering uric acid and relieving gout.

The invention relates to the field of preparation and application of biological peptides, in particular to a swelling hippocampal peptide and application thereof in preparation of uric acid reducing and gout resisting products. The amino acid sequence is shown as SEQ ID NO.1. The uric acid reducing effect of the compound is proved through in-vitro xanthine oxidase (XOD) and adenosine deaminase (ADA) inhibition experiments and cell experiments; on the basis, the uric acid reducing and gout resisting activity of the peptide sequence is further verified by means of a hyperuricemia animal model. The achievement provides a solid theoretical support for high-value development and utilization of the hippocampus japonicus and research and development of uric acid reducing and gout resisting related products.

The invention provides application of indole-3-lactic acid in preparation of uric acid reducing products, and relates to the technical field of medicines. The indole-3-lactic acid is found to have a good blood uric acid reducing effect for the first time, a new uric acid reducing medicine component is provided for health-care food, hyperuricemia and related diseases thereof, and the indole-3-lactic acid is small in renal function damage and is a safe and efficient uric acid reducing functional component. The gout treatment mechanism of the indole-3-lactic acid is mainly realized by relieving the inflammatory response of the organism and improving uric acid excretion, and the indole-3-lactic acid has dual effects, is different from the mechanism of the existing medicine, and has unique innovation.

The invention discloses a lactobacillus buchneri complex microbial inoculant and application thereof, and belongs to the technical field of microorganisms. In order to solve the problem of poor direct degradation effect of lactic acid bacteria on uric acid in the prior art, the invention provides a complex microbial inoculant containing lactobacillus buchneri NEFU-1 and NEFU-2, and the complex microbial inoculant has the functions of degrading uric acid, relieving hyperuricemia, degrading inosine and / or guanosine, improving intestinal flora composition and reducing inflammatory factors; the lactobacillus plantarum has important significance on preventing, improving and treating gout and hyperuricemia diseases, has high application value and can be applied to preparation of fermented yoghurt.

The invention relates to the technical field of pharmaceutical preparations, and provides an oral solid preparation for treating gout and a preparation method thereof. The preparation method comprises the following steps: sieving a filling agent, a disintegrating agent, an adhesive and dotenorad to obtain a sieved material; and mixing the sieved material and a lubricant, and tabletting to obtain the oral solid preparation for treating gout, the filling agent is lactose, mannitol and microcrystalline cellulose. By optimizing the prescription and the preparation process, the dissolution rate and bioavailability of the medicine are improved, so that the curative effect is improved; by selecting proper auxiliary materials and preparation types, the stimulation to gastrointestinal tracts is reduced, and the tolerance of patients is improved; the oral solid preparation is convenient to take, accurate in dosage, high in patient compliance and beneficial to long-term treatment; moreover, the preparation method provided by the invention is simple to operate, easy for industrial production and relatively low in cost.

The subject invention provides a method for treating a non-alcoholic fatty liver disease (NAFLD) disease in a subject afflicted therewith comprising administering to the subject a pharmaceutical composition comprising an amount of a compound which is a non-retinoid retinol-binding protein 4 (RBP4) antagonist effective to treat the subject, thereby treating the subject.The subject invention provides a method for treating gout in a subject afflicted therewith comprising administering to the subject a pharmaceutical composition comprising an amount of a compound which is a retinol-binding protein 4 (RBP4) antagonist effective to treat the subject, thereby treating the subject.

A food medicine for reducing blood uric acid and treating gout is characterized in that celery seeds, celery, mulberry fruits, mulberry leaves, sea buckthorn fruit powder, dandelions, rhizoma polygonati, poria cocos and beach kidney grass serve as a basic formula; the auxiliary materials comprise one, several or all of a plurality of formula combinations of ramulus mori, lycium ruthenicum, radix puerariae, Chinese yam, clerodendranthus spicatus, lysimachia christinae hance, acanthopanax, anserine, astragalus membranaceus, purslane, herba cepbalanoplosis segeti, galangal, hovenia dulcis thunb, astragalus membranaceus, luteolin, uric acid-reducing edible probiotics and the like, and are used for treating hyperuricemia and gout.

The subject invention provides a method for treating a non-alcoholic fatty liver disease (NAFLD) disease in a subject afflicted therewith comprising administering to the subject a pharmaceutical composition comprising an amount of a compound which is a non-retinoid retinol-binding protein 4 (RBP4) antagonist effective to treat the subject, thereby treating the subject.The subject invention provides a method for treating gout in a subject afflicted therewith comprising administering to the subject a pharmaceutical composition comprising an amount of a compound which is a retinol-binding protein 4 (RBP4) antagonist effective to treat the subject, thereby treating the subject.

The invention provides a preparation method and application of borneol water with high natural borneol content, and belongs to the technical field of medicines, daily chemicals and aromatherapy. The invention provides a preparation method of borneol water with high natural borneol content, and the borneol water is prepared by directly adopting fresh crushed cinnamomum camphora leaves as a borneol donor based on a two-stage vacuum steam distillation-cyclodextrin reversible carrying coupling process. According to the method, through a'two-stage vacuum steam distillation-cyclodextrin reversible carrying 'coupling process, the content of borneol in a water phase reaches 0.60 + / -0.05 g / 100mL, the chemical purity is greater than or equal to 96%, and meanwhile, long-term clarification and stability are ensured. The obtained borneol water can be effectively used for treating infant eczema, chronic kidney disease related pruritus and relieving / inhibiting pain in the acute outbreak period of gout.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

The present disclosure relates to uricase variant polypeptides and their multimers, as well as uricase conjugates comprising (i) a first domain comprising one of the uricase variant polypeptides conjugated to (ii) a second domain comprising a random coil polypeptide domain. Methods of using the uricase variant polypeptides and uricase conjugates to treat gout, tumor lysis syndrome, and other diseases associated with elevated uric acid levels in body fluids, including blood, are provided. Methods of recombinantly producing the uricase variant polypeptides and uricase conjugates disclosed herein are also provided.

The invention discloses a medicinal and edible traditional Chinese medicine solid beverage for preventing and treating gout and reducing hypertension, hyperglycemia and hyperlipidemia, which comprises 25 medicinal and edible raw materials such as 20-30 parts of chrysanthemum, 15-20 parts of hawthorn and the like, preferably 25 g of chrysanthemum, 35 g of kudzuvine root and the like. The preparation method comprises the following steps: screening, washing, drying, processing by an ancient method, crushing, sieving by a 120-300-mesh sieve, mixing to prepare a material A, and processing into a bag or granular beverage. The beverage is free of toxic and side effects, free of saccharides and chemical additives, and capable of preventing and treating gout and'four highs', promoting excretion and metabolism of uric acid and enhancing immunity; the traditional Chinese medicine composition can soften heart and cerebral vessels, reduce carotid plaques, prevent thrombus and prevent cardiovascular and cerebrovascular diseases, has health-care and health-preserving effects, and is remarkable in curative effect through experimental verification.

The present application relates to the preparation and application field of biological peptide, and more particularly to a hippocampus abdominalis peptide and its application in preparation of products for reducing uric acid and resisting gout. The amino acid sequence is shown as SEQ ID NO. 1, and the present application confirms the uric acid reducing effect through in vitro xanthine oxidase (XOD) and adenosine deaminase (ADA) inhibition experiments and cell experiments; on this basis, the uric acid reducing and gout resisting activity of the peptide sequence is further verified by means of a high uric acid animal model. This achievement provides a solid theoretical support for high-value development and utilization of hippocampus abdominalis, and research and development of products for reducing uric acid and resisting gout.

The utility model relates to external hot compress equipment technical field, specifically is a kind of gout conditioning machine external hot compress equipment, including concave support frame, cotton pad A and slide rail, the concave support frame top is equipped with hot compress mouth, and the concave support frame top is equipped with seat plate;The concave support frame one side top is equipped with pull-out opening, and the slide rail between is equipped with support frame through pull-out opening, and the inner wall of support frame is evenly equipped with thermostatic electric heating tube by bolt from left to right, and the concave support frame inboard is equipped with support frame corresponding pull-out opening bottom;By the slide rail cooperation support frame sliding or return corresponding hot compress mouth bottom, by the thermostatic electric heating tube of support frame inboard constant-temperature heating, to facilitate hot compress operation, by air hole and cotton pad A be cotton fibre and have good air permeability, by seat plate in hot compress mouth top to facilitate personnel sitting posture hot compress.

This invention discloses a benzofuran compound and its application in lowering uric acid activity. Compounds 1-3 were isolated from the fermentation products of the endophytic fungus *Septoriella phragmitis*, with compound 1 being a novel compound. The fermentation products were purified using mixed solvent extraction, normal silica gel column chromatography, and high-performance liquid chromatography to obtain compounds 1-3. The inhibitory activity of compounds 1-3 on xanthine oxidase, a target related to gout symptoms, was tested. Experimental results showed that the novel compound 1 exhibited good inhibitory activity against xanthine oxidase. Molecular docking experiments also demonstrated that compound 1 had a good binding energy to the target protein. Therefore, compound 1 can be used to prepare a natural lead compound for delaying or treating diseases caused by xanthine oxidase, providing a potential therapeutic agent for hyperuricemia and gout.

The invention provides pain-relieving and stasis-dissipating powder for treating soft tissue and gout, and relates to the technical field of traditional Chinese medicines. The pain-relieving and stasis-dissipating powder for treating soft tissue and gout is prepared from cortex phellodendri, fructus gardeniae, frankincense, myrrh, radix et rhizoma rhei, radix angelicae sinensis, radix angelicae and borneol. The pain-relieving and blood stasis-dissipating powder has the effects of promoting blood circulation to remove blood stasis, relieving swelling and pain, clearing heat, eliminating dampness, removing blood stasis and promoting tissue regeneration, and has a remarkable curative effect on early fracture, soft tissue injury, gout, synovitis and the like.

The present disclosure describes topical ketorolac compositions that comprise a eutectic solvent, such as choline chloride and propylene glycol, and methods and uses thereof. The compositions of the present disclosure are capable of delivering an effective amount of ketorolac through the skin and are believed to be useful in treating inflammation and / or pain, such as gout.

The invention relates to application of puerarin peptide in preparation of anti-inflammatory and / or uric acid-reducing drugs, and relates to the technical field of drugs. The preparation method of the kudzuvine root peptide comprises the following steps: taking kudzuvine root, extracting to obtain soluble protein, dialyzing to obtain dialyzed protein, performing enzymolysis to obtain crude polypeptide, and purifying to obtain the kudzuvine root peptide. The puerarin peptide is high in purity and strong in activity, can remarkably inhibit inflammatory reaction, reduce the level of inflammatory factors and effectively relieve inflammatory symptoms, and provides a new efficient natural medicine choice for treatment of inflammatory diseases; meanwhile, the pharmaceutical composition can effectively reduce the serum uric acid level of a hyperuricemia animal model, regulate uric acid transport related gene expression to promote uric acid excretion and improve renal functions and histopathologic injury, shows a good uric acid reducing effect, is high in safety and free of obvious toxic and side effects, and is expected to become an innovative medicine for treating hyperuricemia and gout.

The invention discloses a plaster for gout as well as a preparation method and application thereof, belongs to the technical field of medicines, and aims to solve the problems of poor moisture retention in winter, low transdermal efficiency and strong sensitive skin irritation of the existing external plaster for gout. The plaster comprises the following raw materials: a first component (10-20 parts of indigo naturalis, 20-30 parts of rhubarb and other 10 traditional Chinese medicines) and a second component (0.5-1 part of sea buckthorn fruit polysaccharide, 0.5-1 part of cynomorium songaricum polysaccharide, 2-3 parts of evening primrose oil microcapsules and the like). The preparation method comprises the steps of raw material pretreatment (extraction and crushing), component mixing and plaster forming. The first component ensures the core curative effects of clearing heat, eliminating dampness and activating meridians to stop pain, the second component synergistically solves the problems of skin dryness and transdermal penetration in winter, the modified component ensures the stability, the sensitive skin irritation rate is low, and the traditional Chinese medicine composition is suitable for patients suffering from gouty swelling and pain and skin sensitivity in winter and wide in clinical applicability.

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrade and / or otherwise modulate (e.g., inhibit) NIMA Related Kinase 7 (NEK7). Said chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having one or more disorders or diseases associated with NLRP3 inflammasome activation. Said disorders or diseases include but are not limited to, autoinflammatory and autoimmune disorders (e.g., gout, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease), cardiovascular and metabolic disorders (eg. pericarditis, atherosclerosis, Type 2 diabetes, obesity, and metabolic syndrome), fibrotic disorders (e.g. interstitial lung disease, chronic kidney disease), hematology (eg, anemia of inflammation) and eye disorders (eg. macular degeneration). In embodiments, and while not wishing to be bound by theory, it is believed that the chemical entities described herein directly target (e.g., directly bind to) NEK7, thereby altering (e.g., attenuating) the inflammatory response modulated by the NLRP3 inflammasome. This disclosure also features compositions containing the same as well as methods of using and making the same.

The present invention discloses a compound of formula (I); specifically, the invention relates to a compound shown as a formula (I) or pharmaceutically acceptable salt, stereoisomer, prodrug, deuterated derivative or solvate, and application of the compounds in drugs for treating or preventing pain, gout, epilepsy, insomnia, anxiety disorder, depression, Parkinson's syndrome and other related diseases.

The present application relates to a kind of preparation compositions containing the preparation method of loxoprofen derivative shown in general formula (I).The composition is a kind of analgesic antipyretic for preventing and treating rheumatoid arthritis, rheumatoid arthritis, osteoarthritis, joint deformity, gout, lumbago, neck shoulder wrist syndrome and periodontitis, cold, acute respiratory inflammation, such as postoperative inflammation of the diseases of the drug composition, its composition is characterized in that the mass percentage of loxoprofen derivative is 0.5%-5.0%w / w;Including physiologically acceptable crystal inhibitor;And at least one pH regulator.The pharmaceutical composition provided by the present application, compared with the preparation of loxoprofen derivative external preparation of the current existing technical means or the method reported in the public literature, solves the problem of active ingredient crystallization of such preparation, and achieves good effect.

The invention discloses an auxiliary device for bloodletting treatment of gout. The device comprises a knife body and a grab handle, an adjusting plate is slidably connected into the grab handle, the adjusting plate is connected with an adjusting piece, the adjusting piece is slidably connected into a sliding through groove, the adjusting plate is connected with an abutting block, and the abutting block is slidably connected with a sliding groove in the front end of the knife body; the position of the abutting block can be locked through the cooperation of the fixing clamping teeth at the tail end of the adjusting plate, the elastic piece and the fixing bolt, and therefore the piercing depth of the knife body can be accurately controlled. An injection cavity is formed in the tail end of the grab handle and used for storing medical alcohol, the alcohol is conveyed to the hollow abutting block through the infusion tube, finally, the alcohol seeps out of the liquid outlet in the front end and the sponge pad, and instant disinfection of the incision part is achieved. The problems that a traditional bloodletting tool depends on experience and is high in operation risk and inconvenient to disinfect are effectively solved, and the safety and convenience of treatment are remarkably improved.

The invention relates to an NEK7 inhibitor, a pharmaceutical composition and application of the NEK7 inhibitor. The NEK7 inhibitor has a structural formula as shown in a formula (I). The compound disclosed by the invention has good NEK7 inhibitory activity, and can be used for treating or preventing a plurality of inflammatory pathological diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, atopic dermatitis, ulcerative colitis, Crohn's disease, cancer, osteoarthritis, gout and the like) regulated by NLRP3 inflammasome.

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrade and / or otherwise modulate (e.g., inhibit) NIMA Related Kinase 7 (NEK7). Said chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having one or more disorders or diseases associated with NLRP3 inflammasome activation. Said disorders or diseases include but are not limited to, autoinflammatory and autoimmune disorders (e.g., gout, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease), cardiovascular and metabolic disorders (eg. pericarditis, atherosclerosis, Type 2 diabetes, obesity, and metabolic syndrome), fibrotic disorders (e.g. interstitial lung disease, chronic kidney disease), hematology (eg. anemia of inflammation) and eye disorders (eg. macular degeneration). In embodiments, and while not wishing to be bound by theory, it is believed that the chemical entities described herein directly target (e.g., directly bind to) NEK7, thereby altering (e.g., attenuating) the inflammatory response modulated by the NLRP3 inflammasome. This disclosure also features compositions containing the same as well as methods of using and making the same.

The present disclosure relates to inhibitors of miR-574-5p (SEQ ID NO: 1) for use in intra-articular treatment of a disease selected from the group consisting of osteoarthritis (OA), rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, gout, juvenile arthritis, systemic lupus erythematosus (SLE), Sjögren's syndrome and osteoporosis.

This invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition, its preparation method, and its uses. By mass parts, the raw materials of the traditional Chinese medicine composition include: 20-60 parts of Acorus calamus, 30-50 parts of Citrus aurantium, 20-60 parts of Benzoin, and 40-100 parts of Catechu. The traditional Chinese medicine composition of this invention has simple and natural components, and clear efficacy. It can effectively reduce the levels of XOD, SUA, CRE, BUN, TNF-α, IL-6, D-Lac, and DAO in the serum of a mouse model of gout, and significantly reduce the renal index, demonstrating good efficacy in treating hyperuricemia and / or gout.

The invention relates to the technical field of traditional Chinese medicine pharmacy, and discloses a traditional Chinese medicine composition for reducing uric acid and application thereof, and the traditional Chinese medicine composition comprises the following components in parts by mass: 15-20 parts of ash bark, 20-25 parts of clerodendranthus spicatus, 18-22 parts of astragalus membranaceus, 12-15 parts of prepared polygonum multiflorum, 15-18 parts of rhizoma smilacis glabrae, 8-10 parts of ligusticum wallichii, 10-12 parts of roasted rhizoma atractylodis macrocephalae and 10-15 parts of salt-fried semen plantaginis. The preparation method comprises the three steps of segmented extraction, sustained-release pellet forming and preparation forming. The traditional Chinese medicine composition disclosed by the invention has the high-efficiency performance of reducing uric acid, protecting healthy qi and achieving long-term effect, and can regulate and control a uric acid metabolic pathway in a multi-target manner; the product can be widely applied to the fields of products for treating primary hyperuricemia and gout in a sustained-release period, products for improving hyperuricemia metabolic syndrome, health-care tea for hyperuricemia and high-risk people, gel products for relieving red, swollen and heat pain of joints in an acute attack period of gout and the like, and the preparation process is controllable and easy to industrialize.

The present invention belongs to the technical field of medicine; relates to a crystal form of an 8-chloro-3-pentyl-3,7-dihydro-1H-purin-2,6-dione compound and a preparation method therefor; and particularly relates to a crystal form of a compound as represented by formula (1), a method for preparing the crystal form of the compound as represented by formula (1), a composition and a preparation containing the crystal form, and the use of the crystal form thereof or the composition and the preparation containing the crystal form in the preparation of a drug for reducing uric acid and resisting inflammation and / or treating and / or preventing uric acid diseases and / or gouty diseases.

The application relates to application of a piezoelectric material in preparation of a medicine for treating gout, characterized in that a medicine active ingredient of the medicine comprises the piezoelectric material, the piezoelectric material is barium titanate; the application comprises the following steps: delivering the medicine to a lesion site, applying ultrasonic stimulation to the lesion site, and exciting in-vivo active species degradation of uric acid by the medicine. The piezoelectric material has good piezoelectric catalytic performance, excellent tissue penetration ability, low toxicity and high precision, active species can be controllably excited by means of ultrasonic action at the time of gout attack, uric acid can be efficiently degraded into allantoin which is good in solubility and non-toxic, symptoms can be rapidly relieved, the piezoelectric material can be long-term resident in joints, can keep stable catalytic effect in multiple cycles, and long-term treatment of gout can be realized by single injection, and a new gout treatment scheme which is more effective and more durable is provided.